The widespread use of tobacco in the 20 century has resulted in a lung cancer epidemic extending into the 21 century. Worldwide, 1.3 million lung cancer-related deaths are expected in 2001. In the United States, there will be an estimated 157,400 lung cancer-related deaths in the year 2001, accounting for 28% of all cancer deaths (American Cancer Society statistics). Despite improved methods of...

The promise of antibodies as mediators of effective targeted anticancer therapy is beginning to be fulfilled. In the past few years, two monoclonal antibodies (MAbs) have been approved for selective use by the U.S. Food and Drug Administration (FDA) (Rockville, MD) and incorporated into standard therapy, resulting in improved clinical responses and prolongation of life. The most dramatic clinic...

So far, mAb E48 is the most promising antibody described for specific targeting of head and neck squamous cell carcinoma (HNSCC) in patients. On the basis of its more homogeneous reactivity pattern on HNSCC, the novel mAb U36 may be even better suited for targeting. In this study the biodistribution of mAb U36 was evaluated by radioimmunoscintigraphy (RIS) and biopsy measurements in 10 patients...

KCC2 is a neuron-specific chloride-extruder that shapes cortical development.Changes in the strength of GABAergic synapses brought about by up- and downregulation Cl? extrusion exert major effect on neuronal plasticity network functions.The structural interactions C terminus regulate signaling pathways involved early survival, spinogenesis, glutamatergic synaptic transmission.The recently disco...

Fifteen % or fewer of patients with non-small cell lung cancer (NSCLC) survive 5 years. The current standard of care for patients with locally advanced or metastatic NSCLC is systemic chemotherapy with a two-drug combination regimen that includes a platinum agent. Although systemic chemotherapy reduces the rate of death attributable to lung cancer, disease progression is inevitable and dose-lim...

The t r ihydroxamate bifunctional chelating agent (BCA), trisuccin, has been shown to be a potential ligand for radiolabeling of monoclonal antibodies (MAbs) with rhenium radioisotopes, through an indirect postconjugation approach. The use of this t r ihydroxamate BCA made it possible to prepare stable BCA-MAb conjugates in pure form that could be radiolabeled with carrier-free lSSRe. The antiT...